37654-41-4

Basic information

• Product Name: 6-KETOESTRIOL 6-(O-CARBOXYMETHYL)OXIME
• Synonyms: 6-KETOESTRIOL 6-(O-CARBOXYMETHYL)OXIME;estriol-6-(O-carboxymethyl)oxime;oestriol 6-(O-carboxymethyl)oxime;Estriol-6-(O-carboxymethyl)oxime, 3,16α,17β-Trihydroxy-1,3,5(10)-estratrien-6-one 6-(O-carboxymethyl)oxime, 1,3,5(10)-Estratrien-6-one-3,16α,17β-triol 6-(O-carboxymethyl)oxime;6-Oxoestriol (carboxymethyl)oxime;1,3,5(10)-Estratrien-6-one-3,16α,17β-triol 6-(O-carboxymethyl)oxime;3,16α,17β-Trihydroxy-1,3,5(10)-estratrien-6-one 6-(O-carboxymethyl)oxime
• CAS NO: 37654-41-4
• Molecular Formula: C₂₀H₂₅NO₆
• Molecular Weight: 375.4156
• Mol File: 37654-41-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 593.965°C at 760 mmHg
• Flash Point: 313.019°C
• Appearance: /
• Density: 1.548g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.699
• CAS DataBase Reference: 6-KETOESTRIOL 6-(O-CARBOXYMETHYL)OXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 6-KETOESTRIOL 6-(O-CARBOXYMETHYL)OXIME(37654-41-4)
• EPA Substance Registry System: 6-KETOESTRIOL 6-(O-CARBOXYMETHYL)OXIME(37654-41-4)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 37654-41-4(Hazardous Substances Data)

Usage

General Description

6-KETOESTRIOL 6-(O-CARBOXYMETHYL)OXIME is a synthetic compound that has been investigated for its potential use in hormone replacement therapy. It is a derivative of the naturally occurring hormone, estrogen, and is designed to mimic its effects in the body. Research suggests that this chemical may have potential benefits in treating symptoms of menopause, such as hot flashes and vaginal dryness, as well as reducing the risk of osteoporosis. However, more studies are needed to fully understand its safety and efficacy for use in medical treatments. Additionally, its potential side effects and interactions with other medications need to be thoroughly researched before it can be considered for clinical use.

InChI:InChI=1/C20H25NO6/c1-20-5-4-12-11-3-2-10(22)6-14(11)16(21-27-9-18(24)25)7-13(12)15(20)8-17(23)19(20)26/h2-3,6,12-13,15,17,19,22-23,26H,4-5,7-9H2,1H3,(H,24,25)/b21-16+/t12?,13?,15?,17-,19+,20+/m1/s1

Upstream product

• 7323-86-6 6-Ketoestriol 
• 2921-14-4 (aminooxy)acetic acid hemihydrochloride 
• 2284-32-4 estriol triacetate 
• 645-88-5 aminooxyacetic acid 
• 20295-82-3 O-carboxymethylhydroxylamine hydrochloride 

Relevant articles and documents

Immunoassay of unconjugated estriol in serum of pregnant women monitored by chemiluminescence

6-Oxoestriol-6-(O-carboxymethyl)oxime-aminobutylethyl-isoluminol conjugate was synthesized. This luminogenic estriol derivative enabled us to develop a solid phase immunoassay method for the determination of unconjugated estriol in serum of pregnant women by the measurement of the bound estriol-isoluminol conjugate upon oxidation with a hydrogen peroxide/microperoxidase system. The sensitivity of the assay was 700 pmol/l. Results obtained by radioimmunoassay and the described method showed good agreement (r = 0.95). The chemiluminescent method is applicable in the routine measurement of unconjugated estriol.

Specificity of antibodies to ovarian hormones in relation to the site of attachment of the steroid hapten to the peptide carrier

Estradiol-17β, estriol and progesterone were rendered antigenic by covalent attachment to bovine serum albumin through ring B or C of the steroid molecule. Coupling to lysine residues of the protein was effected via the 6-(O-carboxymethyl)-oximes of the estrogens and via the 6-(carboxymethylene) thioether or the 11α-hemisuccinate of progesterone, by use of the carbodiimide reagent. Antisera to the estradiol 6-conjugate raised in rabbits or goats distinguished estradiol-17β more efficiently from estrone, estradiol-17α and estriol than did antisera to estradiol-17β-hemisuccinate-BSA; neither serum reacted with non-phenolic steroids or non-steroidal estrogens. Antisera to estriol 6-conjugates showed minimal cross-reaction with estradiol-17β and estrone. Rabbit antisera against the progesterone 6-conjugate did not react with phenolic or C19-steroids, cr with corticosterone, and only feebly with 11-deoxycorticosterone and 20α-or 20β-dihydroprogesterone; significant crossreaction occurred with 17β-hydroxyprogesterone and 3β,17α-dihydroxypregn-5-en-20-one (3-4%), Δ5-pregnenolone (8-14%) and with 5β- and 5β-dihydro-progesterone (100%). Sera against the 11-conjugate were better able to recognize changes about the A-ring and failed to cross-react with 5α-dihydroprogesterone ( 3%). Both sera showed greater specificity than reported for antibodies to 20-conjugates of progesterone towards the D-ring and 17-sidechain and were similar in this respect to antibodies elicited by 3-conjugates described in the literature. It is concluded that the site of attachment of steroid haptens to the peptide carrier importantly affects the specificity of the antibodies produced.